Department of Biology, College of Arts and Sciences, Georgia State University, Atlanta, 30303, Georgia.
Department of Biology, College of Arts and Sciences, Georgia State University, Atlanta, 30303, Georgia.
Virology. 2020 Aug;547:7-11. doi: 10.1016/j.virol.2020.05.002. Epub 2020 May 19.
SARS-COV-2 has recently emerged as a new public health threat. Herein, we report that the FDA-approved drug, auranofin, inhibits SARS-COV-2 replication in human cells at low micro molar concentration. Treatment of cells with auranofin resulted in a 95% reduction in the viral RNA at 48 h after infection. Auranofin treatment dramatically reduced the expression of SARS-COV-2-induced cytokines in human cells. These data indicate that auranofin could be a useful drug to limit SARS-CoV-2 infection and associated lung injury due to its antiviral, anti-inflammatory and anti-reactive oxygen species (ROS) properties. Further animal studies are warranted to evaluate the safety and efficacy of auranofin for the management of SARS-COV-2 associated disease.
SARS-CoV-2 最近成为新的公共卫生威胁。在此，我们报告称，美国食品药品监督管理局批准的药物金诺芬在低微摩尔浓度下抑制人细胞中的 SARS-CoV-2 复制。用金诺芬处理细胞可导致感染后 48 小时内病毒 RNA 减少 95%。金诺芬处理显著降低了 SARS-CoV-2 诱导的人细胞细胞因子的表达。这些数据表明，金诺芬可能是一种有用的药物，可以通过其抗病毒、抗炎和抗活性氧 (ROS) 特性来限制 SARS-CoV-2 感染和相关的肺损伤。需要进一步的动物研究来评估金诺芬在管理 SARS-CoV-2 相关疾病中的安全性和疗效。
Zotero 插件
